|Bid||107.22 x 800|
|Ask||107.39 x 900|
|Day's Range||106.84 - 108.04|
|52 Week Range||79.11 - 121.53|
|Beta (5Y Monthly)||0.79|
|PE Ratio (TTM)||29.07|
|Earnings Date||Oct 28, 2021 - Nov 01, 2021|
|Forward Dividend & Yield||5.20 (4.89%)|
|Ex-Dividend Date||Oct 14, 2021|
|1y Target Est||127.01|
AbbVie (NYSE: ABBV) today announced it will present 27 abstracts across its dermatology portfolio, including new analyses evaluating the safety and efficacy of RINVOQ® (upadacitinib) in atopic dermatitis and new data on SKYRIZI® (risankizumab) in psoriasis and psoriatic arthritis, at the 30th European Academy of Dermatology and Venereology (EADV) Congress, to be held virtually on September 29-October 2.
The wild swings are enough to cause many investors to look for safe havens to park their hard-earned cash. Here's why those chose AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Johnson & Johnson (NYSE: JNJ). Prosper Junior Bakiny (AbbVie): Investors looking for safety in this volatile market can't go wrong with AbbVie.
If ABBV closes above 110 on the expiration date, the shares will be called away at 110, leaving the trader with a total gains of $555.